Antibody Therapies Vs. Omicron: Vir Stands Up But Regeneron And Lilly Fail

Regeneron Pledges Update By Early 2022

 
• By Andrew McConaghie

New studies show Regeneron and Lilly’s leading COVID-19 antibody cocktails are ‘inactive’ against Omicron but there is better news for Vir, AstraZeneca and Adagio.

Covid testing lab
The results suggest the most widely used antibody therapies are be 'inactive' against Omicron. • Source: Alamy

More from Clinical Trials

More from R&D